Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma

August 11, 2026 updated by: Zhen-Yu Ding, Sichuan University

Development and Internal Validation of a Clinicopathologic Prognostic Model for Overall Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoimmunotherapy and Esophagectomy: A Multicenter Retrospective Cohort Study

The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy.

Researchers will review existing clinical, pathologic, and follow-up data from 414 patients treated at three medical centers between 2019 and 2025. The study will assess whether routinely available clinicopathologic factors can provide prognostic information beyond postoperative pathologic staging.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

414

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • West China Hospital, Sichuan University
      • Mianzhu, Sichuan, China, 618200
        • Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University)
      • Suining, Sichuan, China, 629000
        • Suining Central Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population was drawn from patients with esophageal squamous cell carcinoma treated at West China Hospital, Sichuan University; Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University); and Suining Central Hospital between 2019 and 2025. Patients received neoadjuvant chemoimmunotherapy followed by esophagectomy as part of routine clinical care.

Description

Inclusion Criteria:

Age 18 to 80 years Histologically confirmed esophageal squamous cell carcinoma Received at least 1 cycle of neoadjuvant chemoimmunotherapy before surgery Underwent subsequent esophagectomy

Exclusion Criteria:

History of other malignancies Preoperative antitumor therapy other than neoadjuvant chemoimmunotherapy Incomplete clinicopathologic or follow-up data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
ESCC Cohort After Neoadjuvant Chemoimmunotherapy and Esophagectomy
This cohort includes patients aged 18-80 years with histologically confirmed esophageal squamous cell carcinoma who received at least one cycle of neoadjuvant chemoimmunotherapy followed by esophagectomy. Patients were treated at three participating medical centers between 2019 and 2025.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: From the date of esophagectomy to death or last follow-up, up to 73 months.
Overall survival is defined as the interval from the date of esophagectomy to death from any cause. Participants alive at last contact are censored on the date of last follow-up.
From the date of esophagectomy to death or last follow-up, up to 73 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sichuan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2026

Primary Completion (Actual)

June 1, 2026

Study Completion (Actual)

June 1, 2026

Study Registration Dates

First Submitted

March 9, 2026

First Submitted That Met QC Criteria

March 18, 2026

First Posted (Actual)

March 23, 2026

Study Record Updates

Last Update Posted (Actual)

August 13, 2026

Last Update Submitted That Met QC Criteria

August 11, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026-Review-263

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe